Drug
MK 1045
MK 1045: highest development phase Phase 2/3, developed by Merck. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK-1045 NCT07570173 | Phase 2/3 | B-cell Acute Lymphoblastic Leukemia |
| MK-1045 NCT07634471 | Phase 2/3 | Follicular Lymphoma |
| MK-1045 NCT07709000 | Phase 2 | Chronic Lymphocytic Leukaemia |
| MK-1045 NCT07519772 | Phase 1/2 | Lymphoma, Non-Hodgkin |
Latest
No recent events.
Follow MK 1045 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.